Scientists have found that functionally more active mesenchymal stem cells
July 26, 2017 Source: Science Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];The application research of stem cells is changing rapidly and developing rapidly. Among the many types of stem cells, mesenchymal stem cells are currently well-prepared stem cell types. The benefits of mesenchymal stem cells for human health have been well documented, especially in promoting angiogenesis. Can we further differentiate mesenchymal stem cells to find optimized stem cells and further enhance their ability to promote angiogenesis? Based on this idea, the subdivision of the function of mesenchymal stem cell subsets has become a new research hotspot.
Han Zhongchao, a professor at the Chinese Academy of Medical Sciences and Peking Union Medical College, first identified the most functionally active cell subsets of placental mesenchymal stem cells and applied for a patent. This is the CD106-positive placental mesenchymal stem cells.
CD106, also known as vascular cell adhesion molecule 1, plays a key role in the role of mesenchymal stem cells in immune regulation and angiogenesis. The team of Academician Han Zhongchao discovered for the first time that CD106 positive cells accounted for about 70% of placental mesenchymal stem cells. Further studies confirmed that placental CD106-positive mesenchymal stem cells have stronger pro-angiogenic activity than other mesenchymal stem cells.
As early as 2003 and 2005, the research team led by Han Zhongchao discovered the role of mesenchymal stem cells in diabetic angiopathy, and its mechanism is to promote angiogenesis. Han Zhongchao's research team has demonstrated its excellent angiogenic activity, and relevant research results have been published in international journals.
The research work is mainly verified by in vitro experiments and in vivo experiments. In vitro, CD106-positive placental mesenchymal stem cells are seeded onto a special gel called matrigel. Next, the stem cells differentiate themselves to form blood vessels while expanding themselves. Compared with CD106-negative mesenchymal stem cells, CD106-positive mesenchymal stem cells form a richer neovascularization on matrigel.
After the blood vessels of the experimental mice were ligated, CD106-positive placental mesenchymal stem cells were injected into the lower limbs of the mice. Experiments have shown that after a while, new blood vessels slowly grow out. Compared with mice injected with normal saline (PBS) and CD106-negative mesenchymal stem cells, experimental mice injected with CD106-positive mesenchymal stem cells developed more abundant blood vessels in the lower extremities.
In addition, by using gel as a carrier, Han Zhongchao's research team also used CD106-positive placental mesenchymal stem cells for the healing of severe burns and diabetic wounds. At present, this new patented product has undergone formal clinical trials and has achieved encouraging results. (Author Wang Weiqiang)
Oat Powder is produced by the specific enzymatic hydrolysis and spray drying technology, so it is called Hydrolyzed oat powder or Enzymolysis Oat Powder. It has a pleasant oat fragrance with creamy mouthfeel and smooth texture. It retains all the soluble nutrients of oats, such as high-quality plant protein, fat, soluble dietary fiber(3-glucan>3%). It is high-viscosity and slightly sweet, easy to digest and absorb. It is stable and good resistance to acid and heat treatment after dissolution in water.
Oat Powder,Oat Milk Powder,Hydrolyzed Oat Flour,Hydrolyzed Oat Powder,Enzymolysis Oat Powder
Xi'an Gawen Biotechnology Co., Ltd , https://www.amulyn-bio.com